Hematologic Disorders in Renal Failure

  • J. Radermacher
  • Karl M. Koch


Even though renal failure also affects the function of white blood cells (1,2) and thrombocytes (3), renal anemia is the main hematologic disturbance of uremia for which well-founded possibilities of therapeutic intervention exist today. The basis for this exceptional and fortunate situation is our advanced understanding of the pathogenesis of renal anemia as well as recent progress in molecular biology. Since this book is devoted to therapy, this chapter will concentrate on renal anemia and its management.


Serum Ferritin Hemodialysis Patient Continuous Ambulatory Peritoneal Dialysis Transferrin Saturation Recombinant Human Erythropoietin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lewis SL, Van Eps LWS: Neutrophil and monocyte alterations in chronic dialysis patients. Am J Kidney Dis 9: 38 1395, 1987.Google Scholar
  2. 2.
    Himmelfarb J, Hakim RM: Biocompatibility and risk of infection in haemodialysis patients. Nephrol Dial Transplant 9 (Suppl 2): 138–144, 1994.PubMedGoogle Scholar
  3. 3.
    Vigano G, Benigni A, Mendogni D, Mingardi G, Mecca G, Remuzzi G: Recombinant human erythropoietin to correct uremic bleeding. Am J Kidney Diseases 18 (1): 44–49, 1991.Google Scholar
  4. 4.
    Neff MS, Kim KE, Persoff M: Hemodynamics of uremic anemia. Circulation 43: 876–883, 1971.PubMedGoogle Scholar
  5. 5.
    Varat MA, Adolph RJ, Fowler NO: Cardiovascular effects of anemia. Am Heart J 83: 415–426, 1972.PubMedGoogle Scholar
  6. 6.
    Silberberg JS, Rahal DP, Patton DR, Sniderman AD: Role of anemia in the pathogenesis of left ventricular hypertrophy in end-stage renal disease. Am J Cardiol 64 (3): 222–4, 1989.PubMedGoogle Scholar
  7. 7.
    Braunwald E: Pathophysiology of heart failure. In: E Braunwald, ed, Heart Disease: A Textbook of Cardiovascular Medicine. W.B. Saunders, Philadelphia, pp 393–403, 1992.Google Scholar
  8. 8.
    Eschbach J, Adamson J: Anemia of end-stage renal disease. Kidney Int 28: 1–5, 1985.PubMedGoogle Scholar
  9. 9.
    Cambi V, David S: The hematopoietic system in renal failure. Contrib Nephrol 106: 43–52, 1994.PubMedGoogle Scholar
  10. 10.
    Bogin E, Massry S, Levi J, Mdaldeti M, Bristol G, Smith J: Effect of parathyroid hormone on osmotic fragility of human erythrocytes. J Clin Invest 69: 1017–1025, 1982.PubMedGoogle Scholar
  11. 11.
    Akmal M, Telfer N, Ansari A, Massry S: Red blood cell survival in chronic renal failure: role of secondary hyperparathyroidism. J Clin Invest 76: 1695–1698, 1985.PubMedGoogle Scholar
  12. 12.
    Barbour GL: Effect of parathyroidectomy on anemia in chronic renal failure. Arch Intern Med 139: 889–891, 1979.PubMedGoogle Scholar
  13. 13.
    Rao DS, Shih M-S, Mohini R: Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 328: 171–175, 1993.PubMedGoogle Scholar
  14. 14.
    Jacob H, Amsden T: Acute hemolytic anemia with rigid red cells in hypophosphatemia. N Engl J Med 285: 1146–1150, 1971.Google Scholar
  15. 15.
    Eschbach JW: Erythropoietin: the promise and the facts. Kidney Int 45 (Suppl 44): S70 - S76, 1994.Google Scholar
  16. 16.
    Cotes PM, Pippard MJ, Reid CD, Winearls CG, Oliver DO, Royston JP: Characterization of the anaemia of chronic renal failure and the mode of its correction by a preparation of human erythropoietin (r-HuEPO). An investigation of the pharmacokinetics of intravenous erythropoietin and its effects on erythrokinetics. Q J Med 70 (262): 113–37, 1989.PubMedGoogle Scholar
  17. 17.
    Garcia J, Ebbe S, Hollander L, Cutting H, Miller M, Cronkite E: Radioimmunoassay of erythropoietin: circulating levels in normal and polycythemic human beings. J Lab Clin Med 99: 624–635, 1982.PubMedGoogle Scholar
  18. 18.
    McGonigle RJS, Wallin JD, Shadduck RK, Fisher JW: Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int 25: 437–444, 1984.PubMedGoogle Scholar
  19. 19.
    Eckardt K-U, Tan CC, Ratcliffe PJ, Kurtz A: Accumulation of Erythropoietin mRNA in rat liver and kidneys. In: Bauer C, Koch KM, Scigalla P, Wieczorek L, eds, ErythropoietinMolecular Physiology and Clinical Applications. Marcel Dekker, New York, pp 67–76, 1993.Google Scholar
  20. 20.
    Naets JP, Garcia JF, Tousaaint C, Buset M, Waks D: Radio-immunoassay of erythropoietin in chronic uraemia or anephric patients. Scand J Haematol 37: 390–394, 1986.PubMedGoogle Scholar
  21. 21.
    Bachmann S, Le HM, Eckardt KU: Co-localization of erythropoietin mRNA and ecto-5’-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. J Histochem Cytochem 41 (3): 335–341, 1993.PubMedGoogle Scholar
  22. 22.
    Eckardt KU, Kurtz A: The biological role, site, and regulation of erythropoietin production. Adv Nephrol Necker Hosp 21 (203): 203–233, 1992.PubMedGoogle Scholar
  23. 23.
    Eckardt K-U, Kurtz A, Bauer C: Regulation of erythropoietin formation is related to proximal tubular function. Am J Physiol 256: 942–947, 1989.Google Scholar
  24. 24.
    Pagel H, Jelkmann W, Weiss C: A comparison of the effects of renal artery constriction and anemia on the production of erythropoietin. Pflugers Arch 413: 62–66, 1988.PubMedGoogle Scholar
  25. 25.
    Caro J, Brown S, Miller O, Murray T, Erslev AJ: Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med 93: 449–458, 1979.PubMedGoogle Scholar
  26. 26.
    Radtke HW, Claussner A, Erbes PM, Scheuermann EH, Schoeppe W, Koch KM: Serum erythropoietin concentration in chronic renal failure: relationship to degree of anemia and excretory renal function. Blood 54: 877–884, 1979.PubMedGoogle Scholar
  27. 27.
    Corazza F, Bergmann P, Dratawa M, Guns M, Fondu P: Responsiveness to recombinant erythropoietin therapy in end-stage renal disease-an analysis of the predictive value of several biological measurements, including circulating erythroid progenitors. Nephrol Dial Transplant 7: 311–317, 1992.PubMedGoogle Scholar
  28. 28.
    Eschbach JW, Adamson JW, Cook JD: Disorders of red blood cell production in uremia. Arch Intern Med 126: 81 2815, 1970.Google Scholar
  29. 29.
    Radtke HW, Frei U, Erbes PM, Schoeppe W, Koch KM: Improving anemia by hemodialysis: effect on serum erythropoietin. Kidney Int 17: 382–387, 1980.PubMedGoogle Scholar
  30. 30.
    Eschbach JW, Adamson JW: Hematologic consequences of renal failure. In: Brenner B, Rector FC, eds, The Kidney. WB Saunders, Philadelphia, pp 2019–2035, 1991.Google Scholar
  31. 31.
    Aoki I, Nishijima K, Homori M, Nakahara K, Higashi K, Ishikawa K: Responsiveness of bone marrow erythroid progenitors (CFU-E and BFU-E) to recombinant human erythropoietin (rh-Ep) in vitro in multiple myeloma. Br J Haematol 81: 463–469, 1992.PubMedGoogle Scholar
  32. 32.
    Blumberg A: Pathogenese der renalen Anämie. Nephron 51 (Suppl 1): 15–19, 1989.PubMedGoogle Scholar
  33. 33.
    Eschbach JW, Haley NR, Egrie JC, Adamson JW: A comparison of the responses to recombinant human erythropoietin in normal and uremic subjects. Kidney Im 43: 407–416, 1992.Google Scholar
  34. 34.
    Frei U, Wilks MF, Boehmer S, Crisp LN, Schwarzrock R, Stiekema JC, Koch KM: Gastrointestinal blood loss in haemodialysis patients during use of a low-molecular-weight heparinoid anticoagulant. Nephrol Dial Transplant 3(4):435439, 1988.Google Scholar
  35. 35.
    Koch KM, Pastyna WD, Shaldon S, Werner E: Anemia of the regular hemodialysis patient and its treatment. Nephron 14: 405–419, 1974.Google Scholar
  36. 36.
    MacDougall IC: Monitoring of iron status and iron supplementation in patients treated with erythropoietin. Curr Opin Nephrol Hypertens 3 (6): 620–625, 1994.Google Scholar
  37. 37.
    Van Wyck DB, Stivelman JC, Ruiz J, Kirlin LF, Katz MA, Ogden DA: Iron status in patients receiving erythropoietin for dialysis associated anemia. Kidney Int 35: 712–716, 1989.PubMedGoogle Scholar
  38. 38.
    Worwood M: Serum ferritin. Clin Sci 70: 215–220, 1986.PubMedGoogle Scholar
  39. 39.
    Rosenberg ME: Role of transferrin measurement in monitor ing iron status during recombinant human erythropoietin therapy. Dial Transplant 21: 81–90, 1992.Google Scholar
  40. 40.
    Hampers CL, Streiff R, Nathan DG, Snyder D, Merrill JP: Megaloblastic hematopoiesis in uremia and in patients on long-term hemodialysis. N Engl J Med 276: 551–554, 1967.PubMedGoogle Scholar
  41. 41.
    Ono K, Hisasue Y: Is folate supplementation necessary in hemodialysis patients on erythropoietin therapy. Clin Nephrol 38 (5): 290–292, 1992.PubMedGoogle Scholar
  42. 42.
    Kaiser L, Schwartz KA: Aluminium induced anemia. Am J Kidney Dis 6: 348–352, 1985.PubMedGoogle Scholar
  43. 43.
    Swartz R, Dombrouski J, Burnatowska J, Hledin M, Mayor G: Microcytic anemia in dialysis patients: reversible marker of aluminium toxicity. Am J Kidney Dis 9: 217–223, 1987.PubMedGoogle Scholar
  44. 44.
    Mladenovic J: Aluminium inhibits erythropoiesis in vitro. J Clin Invest 81: 1661–1665, 1988.PubMedGoogle Scholar
  45. 45.
    Miller ME, Rort M, Parving HH, Howard D, Reddingt I, Valeri CR, Stohlman F. pH effect on erythropoietin response to hypoxia. N Engl J Med 288: 706–710, 1973.PubMedGoogle Scholar
  46. 46.
    Onoyama K, Motomura K, Makita H, Kiyama S, Takata Y, Urabe A: Effects of long-term captopril on angiotensin II and erythropoietin levels and recovery from hemorrhagic anemia in rats. Curr Ther Res 41: 472–477, 1987.Google Scholar
  47. 47.
    Pratt MC, Lewis BN, Walker RJ, Bailey RR, Shand BI, Livesey J: Effect of angiotensin converting enzyme inhibitors on erythropoietin concentrations in healthy volunteers. Br J Clin Pharmacol 34 (4): 363–365, 1992.PubMedGoogle Scholar
  48. 48.
    Kamper A-L, Nielsen OJ: Effect of enalapril on haemoglobin and serum erythropoietin in patients with chronic nephropathy. Scand J Clin Lab Invest 50: 611–618, 1990.PubMedGoogle Scholar
  49. 49.
    Hirakata H, Onoyama K, Iseki K, Kumagai H, Fujimi S, Omae T: Worsening of anemia induced by long term use of captopril in hemodialysis patients. Am J Nephrol 4: 355–360, 1984.PubMedGoogle Scholar
  50. 50.
    Graafland AD, Doorenbos CJ, Van Saase SJ: Enalaprilinduced anemia in two kidney transplant recipients. Transplant Int 5 (1): 51–3, 1992.Google Scholar
  51. 51.
    Jelkmann W: Erythropoietin: structure, control of production, and function. Physiol Rev 72 (2): 449–89, 1992.PubMedGoogle Scholar
  52. 52.
    Taniguchi S, Shibuya T, Harada M, Niho Y: Prostaglandin-mediated suppression of in vitro growth of erythroid progenitor cells. Kidney Im 36 (4): 712–718, 1989.Google Scholar
  53. 53.
    Krantz SB: Pathogenesis and treatment of the anemia of chronic disease. Am J Med Sci 307 (5): 353–359, 1994.PubMedGoogle Scholar
  54. 54.
    Adamson JW, Eschbach JW: Management of the anaemia of chronic renal failure with recombinant human erythropoietin. Q J Med 73: 1093–1101, 1989.PubMedGoogle Scholar
  55. 55.
    Powe NR, Griffiths RI, Greer JW, Watson AJ, Anderson GF, de LG, Herbert RJ, Eggers PW, Milam RA, Whelton PK: Early dosing practices and effectiveness of recombinant human erythropoietin. Kidney Im 43 (5): 1125–1133, 1993.Google Scholar
  56. 56.
    Goodnough LT, Strasburg D, Riddell J, Verbrugge D, Wish J: Has recombinant human erythropoietin therapy minimized red-cell transfusions in hemodialysis patients? Clin Nephrol 41 (5): 303–307, 1994.PubMedGoogle Scholar
  57. 57.
    Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end stage renal disease with recombinant human erythropoietin. N Engl J Med 316: 73–78, 1987.PubMedGoogle Scholar
  58. 58.
    Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM: Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2: 1175–1178, 1986.PubMedGoogle Scholar
  59. 59.
    Grimm PC, Sinai-Triemann L, Sekiya NM, Robertson LS Robinson BJ, Fine RN, Ettenger RB: Effects of recombinant human erythropoietin on HLA sensitization and cell mediated immunity. Kidney Int 38: 12–18, 1990.PubMedGoogle Scholar
  60. 60.
    Ettenger RB, Marik J, Grimm P: The impact of recombinant human erythropoietin therapy on renal transplantation. Am J Kidney Dis 18 (4) (Suppl 1 ): 57–61, 1991.Google Scholar
  61. 61.
    Frei U, Nonnast-Daniel B, Koch KM: Erythropoietin and Hypertonie. Klin Wochenschr 66 (18): 914–919, 1988.PubMedGoogle Scholar
  62. 62.
    MacDougall IC, Lewis NP, Saunders MJ, Cochlin DL, Davies ME, Hutton RD, Fox KAA, Coles GA, Williams JD: Long term cardiorespiratory effects of amelioration of renal anemia by erythropoietin. Lancet 335 (8688): 489–493, 1990.PubMedGoogle Scholar
  63. 63.
    Mayer G, Thum J, Cada EM, Stummvoll HK, Graf H: Working capacity is increased following recombinant human erythropoietin treatment. Kidney Int 34: 525–528, 1988.PubMedGoogle Scholar
  64. 64.
    Barany P, Freyschuss U, Pettersson E, Bergstrom J: Treatment of anemia in haemodialysis patients with erythropoietin: long term effects on exercise capacity. Clin Sci 84: 441–447, 1993.PubMedGoogle Scholar
  65. 65.
    Barany P, Pettersson E, Ahlberg M, Hultmann E, Bergstrom J: Nutritional assessment in anemic hemodialysis patients treated with recombinant human erythropoietin. Clin Nephrol 35: 270–279, 1991.PubMedGoogle Scholar
  66. 66.
    Bommer J, Alexiou C, Müller-Bühl U, Eifert J, Ritz E: Recombinant human erythropoietin therapy in hemodialysis patients—dose determination and clinical experience. Nephrol Dial Transplant 2: 238–242, 1987.PubMedGoogle Scholar
  67. 67.
    Bommer J, Kugel M, Schwbel B, Ritz E, Barth HP, Seelig R: Improved sexual function during recombinant human erythropoietin therapy. Nephrol Dial Transplant 5: 204–207, 1990.PubMedGoogle Scholar
  68. 68.
    Marsh JT, Brown WS, Wolcott D, Carr CR, Harper R, Schweitzer SV, Nissenson AR: R-HuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney Int 39: 155–163, 1991.PubMedGoogle Scholar
  69. 69.
    Radermacher J, Koch KM: Erythropoietin and hypertension. In: Bauer C, Koch KM, Scigalla P, Wieczorek L, eds, Erythropoietin—Molecular Physiology and Clinical Applications. Marcel Dekker, New York, pp 129–152, 1993.Google Scholar
  70. 70.
    London GM, Zins B, Pannier B, Naret C, Berthelot J-M, Jacquot C, Safar M, Drueke T: Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int 36: 878–892, 1989.PubMedGoogle Scholar
  71. 71.
    Zehnder C, Zuber M, Sulzer M, Meyer B, Straumann E, Jenzer H-R, Blumberg A: Influence of long-term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialyzed patients. Nephron 61: 21–25, 1992.PubMedGoogle Scholar
  72. 72.
    Pascual J, Teruel JL, Moya JL, Liano F, Jimenez MM, Ortuno J: Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. Clin Nephrol 35 (6): 280–287, 1991.PubMedGoogle Scholar
  73. 73.
    Löw-Friedrich I, Grutzmacher P, Marz W, Bergmann M, Schoeppe W: Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients. Am J Nephrol 11 (1): 54–60, 1991.PubMedGoogle Scholar
  74. 74.
    Satoh K, Masuda T, Ikeda Y, Kurokawa S, Kamata K, Kikawada R, Takamoto T, Marumo F: Hemodynamic changes by recombinant erythropoietin therapy in hemodialyzed patients. Hypertension 15 (3): 262–266, 1990.PubMedGoogle Scholar
  75. 75.
    McGregor E, McClaughlin K, Lowe GDO, Rodger RSC, Junor BJR, Briggs JD: abstract-Changes in blood viscosity,and left ventricular mass with correction of anemia by renal transplantation and erythropoietin. J Am Soc Nephrol 2 (3): 382, 1991.Google Scholar
  76. 76.
    Klaus D, Schwarze D, Lederle RM, Saul F: Influence of erythropoietin in hemodynamics, left ventricular performance and neurohumoral factors in end-stage renal failure with left ventricular hypertrophy. Nieren Hochdruckkr 20 (1): 28–35, 1991.Google Scholar
  77. 77.
    Martinez VA, Bardaji A, Garcia C, Ridao C, Richart C, Oliver JA: Long-term myocardial effects of correction of anemia with recombinant human erythropoietin in aged patients on hemodialysis. Am J Kidney Dis 19 (4): 353–357, 1992.Google Scholar
  78. 78.
    Tagawa H, Nagano M, Saito H, Umezu M, Yamakado M: Echocardiographic findings in hemodialysis patients treated with recombinant human erythropoietin: proposal for a hematocrit most beneficial to hemodynamics. Clin Nephrol 35 (1): 35–38, 1991.PubMedGoogle Scholar
  79. 79.
    Silverberg JS, Racine N, Barre P, Sniderman AD: Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 6 (1): S1 - S4, 1989.Google Scholar
  80. 80.
    Low I, Grutzmacher P, Bergmann M, Schoeppe W: Echocardiographic findings in patients on maintenance hemodialysis substituted with recombinant human erythropoietin. Clin Nephrol 31: 26–30, 1989.PubMedGoogle Scholar
  81. 81.
    Canella G, LaCanna G, Sandrini M, Gaggiotti M, Nordio G, Movilli E, Mombelloni S, Visioli O, Maiorca R: Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients. Nephrol Dial Transplant 6 (1): 31–37, 1991.Google Scholar
  82. 82.
    Schütterle G, Kramer W, Schfer R, Kaufmann J, Wizemann V: Cardiological findings in patients with end-stage renal failure under treatment with erythropoietin. In: Pagel H, Weiss C, Jelkmann W, eds, Pathophysiology and Pharmacology of Erythropoietin. Springer-Verlag, Berlin, Heidelberg, pp 177–180, 1992.Google Scholar
  83. 83.
    Wizemann V, Schäfer R, Kramer W: Follow-up of cardiac changes induced by anemia compensation in normotensive hemodialysis patients with left ventricular hypertrophy. Nephron 64: 202–206, 1993.PubMedGoogle Scholar
  84. 84.
    Silberberg JS, Barre PE, Prichard SS, Sniderman AD: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36 (2): 286–290, 1989.PubMedGoogle Scholar
  85. 85.
    Sniderman AD, Silberberg J, Prichard S, Barré PE: Anemia and left ventricular function in end-stage renal disease. In: Parfrey PS, Harnett JD, eds, Cardiac Dysfunction in Chronic Uremia. Kluwer Academic Publishers, Boston, pp 161–170, 1992.Google Scholar
  86. 86.
    Wizemann V, Kaufmann J, Kramer W: Effect of erythropoietin on ischemia tolerance in anemic hemodialysis patients with confirmed coronary artery disease. Nephron 62: 161–165, 1992.PubMedGoogle Scholar
  87. 87.
    Eschbach JW, Aquiling T, Haley NR, Fan MH, Blagg CR: The long-term effects of recombinant human erythropoietin on the cardiovascular system. Clin Nephrol 38 (Suppl 1): S98 - S103, 1992.PubMedGoogle Scholar
  88. 88.
    El Shahawy M, Francis R, Akmal M, Massry SG: Recombinant human erythropoietin shortens the bleeding time and corrects the abnormal platelet aggregation in hemodialysis patients. Clin Nephrol 41 (5): 308–313, 1994.PubMedGoogle Scholar
  89. 89.
    Livio M, Boonigni A, Remuzzi G: Coagulation abnormalities in uremia. Semin Nephrol 5: 82–90, 1985.PubMedGoogle Scholar
  90. 90.
    Edmunds ME, Walls J, Tucker B, Baker LR, Tomson CR, Ward M, Cunningham J, Moore R, Winearls CG: Seizures in haemodialysis patients treated with recombinant human erythropoietin. Nephrol Dial Transplant 4: 1065–1069, 1989.PubMedGoogle Scholar
  91. 91.
    Bergrem H, Danielson BG, Eckardt K-U, Kutrtz A, Stridsberg M: A case of antierythropoietin antibodies following recombinant human erythropoietin treatment. In: Bauer C, Koch KM, Scigalla P, Wieczorek L, eds, ErythropoietinMolecular Physiology and Clinical Applications. Marcel Dekker, New York, pp 265–273, 1993.Google Scholar
  92. 92.
    Bahlmann J, Schoter KH, Scigalla P, Gurland HJ, Hilfenhaus M, Koch KM, Muthny FA, Neumayer HH, Pommer W, Quelhorst E, Sieberth HG, Weber U: Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: a controlled study. Contrib Nephrol 88 (90): 90106, 1991.Google Scholar
  93. 93.
    Abraham PA, Macres MG: Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. J Am Soc Nephrol 2 (4): 927–936, 1991.PubMedGoogle Scholar
  94. 94.
    Canadian-Erythropoietin-Study-Group: Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J 300 (6724): 573–578, 1990.Google Scholar
  95. 95.
    Duling BR, Pitman RN: Oxygen tension: dependent or independent variables in local control of blood flow? Fed Proc 34 (11): 2012–2019, 1975.PubMedGoogle Scholar
  96. 96.
    Pascual J, Teruel JL, Marcen R, Gamez C, Liano F, Ortuno J: Blood pressure after three different forms of correction of anemia in hemodialysis. Int J Artif Organs 15 (7): 393–396, 1992.PubMedGoogle Scholar
  97. 97.
    Williams B, Edmunds ME, Thompson JP, Burton PR, Feehally J, Walls J: Does increasing haemoglobin concentration and haematocrit have a pressor effect in dialysis patients. Nephrol Dial Transplant 4: 878–891, 1989.Google Scholar
  98. 98.
    Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M: Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 87: 59785982, 1990.Google Scholar
  99. 99.
    Heidenreich S, Rahn KH, Zidek W: Direct vasopressor effect of recombinant human erythropoetin on renal vascular resistance. Kidney Int 39 (2): 259–265, 1991.PubMedGoogle Scholar
  100. 100.
    Tsukada H, Ishimitsu T, Ogawa Y, Sugimoto T, Yagi S: Direct vasopressor effects of erythropoietin in genetically hypertensive rats. Life Sci 52 (17): 1425–1434, 1993.PubMedGoogle Scholar
  101. 101.
    Radermacher J, Bode-Böger SM, Böger R, Frölich JC, Koch K-M: Erythropoietin enhances norepinephrine induced contractions via modulation in prostaglandin balance in rabbit and human arteries. Blood Purif 10 (2): 79–80, 1992.Google Scholar
  102. 102.
    Takayama K: Changes in endothelial vasoactive substances and blood coagulation and fibrinolysis functions under recombinant human erythropoietin therapy in hemodialysis patients. Nippon Jinzo Gakkai Shi 35 (2): 179–188, 1993.PubMedGoogle Scholar
  103. 103.
    Carlini R, Obialo CI, Rothstein M: Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. Am J Hypertens 6 (2): 103–107, 1993.PubMedGoogle Scholar
  104. 104.
    Bode-Böger S, Böger RH, Kuhn M, Radermacher J, Frölich JC: Endothelin release and shift in prostaglandin balance are involved in the modulation of vascular tone by recombinant erythropoietin. J Cardiovasc Pharmacol 20 (Suppl 12): S25–S28, 1992.PubMedGoogle Scholar
  105. 105.
    Caravaca F, Pizarro JL, Arrobas M, Cubero JJ, Garcia MC, Perez MM: Antiplatelet therapy and development of hypertension induced by recombinant human erythropoietin in uremic patients. Kidney Int 45 (3): 845–851, 1994.PubMedGoogle Scholar
  106. 106.
    Winearls CG: Treatment of anaemia in haemodialysis patients with recombinant erythropoietin. Nephron 51 (Supp 1 1)): 26–28, 1989.PubMedGoogle Scholar
  107. 107.
    Casati S, Passerini P, Campise MR, Graziani G, Cesana B, Perisic M, Ponticelli C: Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J Clin Res Ed 295(6605):10171020, 1987.Google Scholar
  108. 108.
    Sharpe PC, Desai ZR, Morris TC: Increase in mean platelet volume in patients with chronic renal failure treated with erythropoietin. J Clin Pathol 47 (2): 159–161, 1994.PubMedGoogle Scholar
  109. 109.
    Bommer J, Müller-Bühl U, Ritz E, Eifert J: Recombinant human erythropoietin in anaemic patients on haemodialysis (letter). Lancet 1: 392, 1987.PubMedGoogle Scholar
  110. 110.
    Wirtz JJJM, Van Esser JWJ, Hamulyak K, Leunissen KML, Van Hooff JP: The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients. Clin Nephrol 38(5):277–282,1992.Google Scholar
  111. 111.
    Bennett WM: A multicenter clinical trial of epoetin beta for anemia of end-stage renal disease. J Am Soc Nephrol 1 (7): 990–998, 1991.PubMedGoogle Scholar
  112. 112.
    Canadian-Erythropoietin-Study-Group: Effect of recombinant human erythropoietin therapy on blood pressure in hemodialysis patients. Am J Nephrol 11 (1): 23–26, 1991.Google Scholar
  113. 113.
    Churchill DN, Muirhead N, Goldstein M, Posen G, Fay W, Beecroft ML, Gorman J, Taylor DW: Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin. J Am Soc Nephrol 4 (10): 1809–1813, 1994.PubMedGoogle Scholar
  114. 114.
    Spinowitz BS, Arslanian J, Charytan C, Golden RA, Rascoff J, Galler M: Impact of epoetin beta on dialyzer clearance and heparin requirements. Am J Kidney Dis 18 (6): 668–673, 1991.PubMedGoogle Scholar
  115. 115.
    Veys N, Vanholder R, De Cuyper K, Ringoir S: Influence of erythropoietin on dialyzer reuse, heparin need, and urea kinetics in maintenance hemodialysis patients. Am J Kidney Dis 23 (1): 52–59, 1994.PubMedGoogle Scholar
  116. 116.
    Grützmacher P, Bergmann M, Weinreich T, Nattermann U, Reimers E, Pollok M: Beneficial and adverse effects of correction of anaemia by recombinant human erythropoietin in patients on maintenance haemodialysis. Contrib Nephrol 66: 104–113, 1988.PubMedGoogle Scholar
  117. 117.
    Canaud B, Polito-Bouloux C, Garred LJ, Rivory J-P, Donnadieu P, Taib J, Florence P, Mion C: Recombinant human erythropoietin: 18 months experience in hemodialysis patients. Am J Kidney Dis 15 (2): 169–175, 1990.PubMedGoogle Scholar
  118. 118.
    Garcia DL, Anderson S, Rennke HG, Brenner BM: Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci USA 85 (16): 6142–6146, 1988.PubMedGoogle Scholar
  119. 119.
    The US Recombinant Human Erythropoietin Predialysis Study Group: Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis 18 (1): 50–59, 1991.Google Scholar
  120. 120.
    Abraham PA, Opsahl JA, Rachael KM, Asinger R, Halstenson CE: Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients. Am J Nephrol 10: 128–136, 1990.PubMedGoogle Scholar
  121. 121.
    Kleinmann KS, Schweitzer SU, Perdue ST, Bleifer KH, Abels RI: The use of recombinant human erythropoietin in the correction of anaemia in predialysis patients and its effect on renal function: a double-blind, placebo controlled trial. Am J Kidney Dis 14: 486–495, 1989.Google Scholar
  122. 122.
    Lim VS: Recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 18(4) (Suppl 1 ): 34–37, 1991.Google Scholar
  123. 123.
    Austrian Multicenter Study Group of r-HuEPO in Predialysis Patients: Effectiveness and safety of recombinant human erythropoietin in predialysis patients. Nephron 61: 399–403, 1992.Google Scholar
  124. 124.
    MacDougall IC, Davies ME, Hutton RD, Cavill I, Lewis NP, Coles GA, Williams JD: The treatment of renal anemia in CAPD patients with recombinant human erythropoietin. Nephrol Dial Transplant 5: 950–955, 1990.PubMedGoogle Scholar
  125. 125.
    Frenken LAM, Verberckmoes R, Michielsen P, Koene RAP: Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients. Nephrol Dial Transplant 4: 782–786, 1989.PubMedGoogle Scholar
  126. 126.
    Ashai NI, Paganini EP, Wilson JM: Intravenous versus subcutaneous dosing of epoetin: a review of the literature. Am J Kidney Dis 22 (Suppl 1): 23–31, 1993.PubMedGoogle Scholar
  127. 127.
    Wolfson M, Mundt DJ, Hawley GG: Recombinant human erythropoietin utilization in Department of Veterans Affairs dialysis units. Am J Kidney Dis 24 (2): 184–191, 1994.PubMedGoogle Scholar
  128. 128.
    Hörl WH: Optimal route of administration of erythropoietin in chronic renal failure patients: intravenous versus subcutaneous. Acta Haematol 1 (16): 16–19, 1992.Google Scholar
  129. 129.
    Macdougall IC, Roberts DE, Coles GA, Williams JD: Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet 20 (2): 99–113, 1991.PubMedGoogle Scholar
  130. 130.
    Taylor JE, Belch JJ, Fleming LW, Mactier RA, Henderson IS, Stewart WK: Erythropoietin response and route of administration. Clin Nephrol41(5): 297–302, 1994.Google Scholar
  131. 131.
    Hörl WH: Painless subcutaneous erythropoietin (rHuEPO) injection-is it the panacea. Nephrol Dial Transplant 9 (9): 1224–1225, 1994.PubMedGoogle Scholar
  132. 132.
    Kampf D, Kahl A, Passlick J, Pustelnik A, Eckardt K-U, Ehmer B, Jacobs C, Baumelou A, Grabensee B, Gahl GM: Single-dose kinetics of recombinant human erythropoietin after intravenous, subcutaneous and intraperitoneal administration. Contrib Nephrol 76: 106–111, 1989.PubMedGoogle Scholar
  133. 133.
    Lai KN, Lui SF, Leung JC, Law E, Nicholls MG: Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis. Nephron 57 (4): 394–400, 1991.PubMedGoogle Scholar
  134. 134.
    Schwartz AB, Kahn SB, Kelch KE, Pequignot E: RBC improved survival due to recombinant human erythropoietin explains effectiveness of less frequent, low dose subcutaneous therapy. Clin Nephrol 38 (5): 283–289, 1992.PubMedGoogle Scholar
  135. 135.
    Neff MS, Eiser AR, Slifkin RF, Baum M, Baez A, Gupta S, Amarga E: Patients surviving 10 years of hemodialysis. Am J Med 74 (6): 996–1004, 1983.PubMedGoogle Scholar
  136. 136.
    Ritz E, Zeier M, Schneider P, Jones E: Cardiovascular mortality of patients with polycystic kidney disease on dialysis: is there a lesson to learn? (editorial). Nephron 66 (2): 125–128, 1994.PubMedGoogle Scholar
  137. 137.
    Byrne C, Vernon P, Cohen JP: Effect of age and diagnosis on survival of older patients beginning chronic dialysis. JAMA 271 (1): 34–36, 1994.PubMedGoogle Scholar
  138. 138.
    Barany P, Svedenhag J, Freyschuss U, Bergström J: Physiological effects of correcting anemia in hemodialysis patients to a normal hemoglobin concentration (abstract). Clin Invest 72 (5): B13, 1994.Google Scholar
  139. 139.
    Bell JD, Kincaid WR, Morgan RG, Bunce H, Alperin JB, Sarles HE, Remmers AR: Serum ferritin assay and bone-marrow iron stores in patients on maintenance hemodialysis. Kidney Int 17: 237–241, 1980.PubMedGoogle Scholar
  140. 140.
    Birgegard G, Hallgren R, Killander A: Serum ferritin during infection: a longitudinal study. Scand J Haematol 21: 333–340, 1978.PubMedGoogle Scholar
  141. 141.
    Ali M, Rigolosi R, Fayemi AO, Braun EV, Fascino J, Singer R: Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet i: 652–655, 1982.Google Scholar
  142. 142.
    Bainton DF, Finch CA: The diagnosis of iron deficiency anemia. Am J Med 37: 62–70, 1964.PubMedGoogle Scholar
  143. 143.
    Cavill I: Diagnostic methods. Clin Haematol 11: 259–273, 1982.PubMedGoogle Scholar
  144. 144.
    Macdougall IC, Cavill I, Hulme B, Bain B, McGregor E, McKay P, Sanders E, Coles GA, Williams JD: Detection of functional iron deficiency during erythropoietin treatment: a new approach. Br Med J 304: 225–226, 1992.Google Scholar
  145. 145.
    Cazzola M, Bergamaschi G, Barosi G, Bellotti V, Caldera D, Civiello MM, Quaglini S, Arosio P, Ascari E: Biological and clinical significance of red cell ferritin. Blood 62: 1078–1087, 1983.PubMedGoogle Scholar
  146. 146.
    Beguin Y, Loo M, R Zik S, Sautois B, Lejune F, Rorive G, Fillet G: Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen. Blood 82: 2010 2016, 1993.Google Scholar
  147. 147.
    Moreb J, Poportzer MM, Friedlander MM, Konijn AN, Hershko C: Evaluation of iron status in patients on chronic haemodialysis: relative usefulness of bone marrow haemosiderin, serum ferritin, transferrin saturation, mean corpuscular volume and red cell protoporphyrin. Nephron 35: 196–200, 1983.PubMedGoogle Scholar
  148. 148.
    Garrett S, Worwood M: Zinc protoporphyrin and iron-deficient erythropoiesis. Acta Haematol 91 (1): 21–25, 1994.PubMedGoogle Scholar
  149. 149.
    Levin NW, Lazarus JM, Nissenson AR: National Cooperative rHu Erythropoietin Study in patients with chronic renal failure: an interim report. Am J Kidney Dis 22 (Suppl 1): 3–12, 1993.PubMedGoogle Scholar
  150. 150.
    Anderson RJ, Melikian DM, Gambertoglio JG, Berns AS, Cadnapaphornchai J, Egan DJ, Goldberg JP, Henrich WL, Hicks DL, Kovaichik MT, Olin DB: Prescribing medication in long-term dialysis units. Arch Int Med 142: 1305–1308, 1982.Google Scholar
  151. 151.
    Gokal R, Millard PR, Weatherall DJ, Callender STE, Ledingham JGG, Oliver DO: Iron metabolism in haemodialysis patients. Q J Med 48: 369–391, 1979.PubMedGoogle Scholar
  152. 152.
    Cook JD, Dassenko S, Skikne BS: Serum transferrin receptor as an index of iron absorption. J Lab Clin Med 75: 603–609, 1990.Google Scholar
  153. 153.
    Schaefer RM, Schaefer L: Management of iron substitution during r-HuEPO therapy in chronic renal failure patients. Erythropoiesis 3: 71–75, 1992.Google Scholar
  154. 154.
    MacDougall IC, Hutton RD, Cavill I, Coles GA, Williams JD: Poor response to treatment of renal anemia with erythropoietin corrected by iron given intravenously. Br Med J 299: 157–158, 1989.Google Scholar
  155. 155.
    Watson A: Iron management during treatment with recombinant human erythropoietin in chronic renal failure. J Clin Pharmacol 33: 1134–1138, 1993.PubMedGoogle Scholar
  156. 156.
    Van Wyck DB: Iron management during recombinant human erythropoietin therapy. Am J Kidney Dis 14 (Suppl 1): 913, 1989.Google Scholar
  157. 157.
    Auerbach M, Witt D, Toler W, Fierstein M, Lerner RG, Ballard H: Clinical use of the total dose intravenous infusion of iron dextran. J Lab Clin Med 111 (5): 566–570, 1988.PubMedGoogle Scholar
  158. 158.
    Porter J, Jick H: Drug-induced anaphylaxis, convulsions, deafness, and extrapyramidal symptoms. Lancet 1: 587–588, 1977.PubMedGoogle Scholar
  159. 159.
    Zipf RJ: Fatal anaphylaxis after intravenous iron dextran. J Forensic Sci 20 (2): 326–333, 1975.PubMedGoogle Scholar
  160. 160.
    Granoleras C, Oulès R, Branger B, Fourcade J, Shaldon S: Iron supplementation of hemodialysis patients receiving recombinant human erythropoietin therapy. In: Bauer C, Koch KM, Scigalla P, Wieczorek L, eds, Erythropoietin-Molecular Physiology and Clinical Applications. Marcel Dekker, New York, pp 211–216, 1993.Google Scholar
  161. 161.
    Maiorca R, Cancarini G, Manili L, Brunorio G, Camerini C, Strada A, Feller P: CAPD is a first class treatment: results of an eight-year experience with a comparison of patient and method survival in CAPD and hemodialysis. Clin Nephrol 30 (Suppl 1): S3 - S7, 1988.PubMedGoogle Scholar
  162. 162.
    Salahudeen AK, Keavey PM, Hawkins T, Wilkinson R: Is anemia during continous ambulatory peritoneal dialysis really better than during haemodialysis. Lancet ii: 1046–1049, 1983.Google Scholar
  163. 163.
    Maluche HH, Faugere MC: Aluminium-related bone disease. Blood Purif 6: 1–15, 1988.Google Scholar
  164. 164.
    McCarthy JT, Milliner DS, Johnson WJ: Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity. Q J Med 74 (275): 257–276, 1990.PubMedGoogle Scholar
  165. 165.
    Neff MS, Goldberg J, Slifkin RF, Eiser AR, Calamia V: A comparison of androgens for anemia in patients on hemodialysis. N Engl J Med 304: 871–875, 1981.PubMedGoogle Scholar
  166. 166.
    Hendler ED, Solomon L: Androgen therapy in hemodialysis patients: 1. Effects on red cell oxygen transport. Kidney Int 31: 100–106, 1987.PubMedGoogle Scholar
  167. 167.
    Besarab A, Caro J, Jarrell BE, Francos G, Erslev AJ: Dynamics of erythropoiesis following renal transplantation. Kidney Int 32: 526–536, 1987.PubMedGoogle Scholar
  168. 168.
    Eckardt K-U, Frei U, Kliem V, Bauer C, Koch KM, Kurtz A: Role of excretory graft function for erythropoietin formation after renal transplantation. Eur J Clin Invest 20: 564–574, 1990.Google Scholar
  169. 169.
    McGrath BP, Ibels LS, Raik E, Hargrave M, Mahony JF, Stewart JH: Erythroid toxicity of azathioprine: macrocytosis and selective marrow hypoplasia. Q J Med 44: 57–63, 1975.PubMedGoogle Scholar
  170. 170.
    Gossmann J, Kachel HG, Schoeppe W, Scheuermann EH: Anemia in renal transplant recipients caused by concomitant therapy with azathioprine and angiotensin-converting enzyme inhibitors. Transplantation 56 (3): 585–589, 1993.PubMedGoogle Scholar
  171. 171.
    Friman S, Nyberg G, Blohme I: Erythrocytosis after renal transplantation: treatment by removal of the native kidneys. Nephrol Dial Transplant 5 (11): 969–973, 1990.PubMedGoogle Scholar
  172. 172.
    Gaston RS, Julian BA, Curtis JJ: Posttransplant erythrocytosis: an enigma revisited. Am J Kidney Dis 24 (1): 1–11, 1994.PubMedGoogle Scholar
  173. 173.
    Fernandez A, Hortal L, Rodriguez JC, Vega N, Plaza C, Palop L: Anemia in dialysis: its relation to acquired cystic disease and serum levels of erythropoietin. Am J Nephrol 11: 11–15, 1991.Google Scholar
  174. 174.
    Eckardt K-U, Möllmann M, Neumann R, Brunkhorst R, Burger H-U, Lonnemann G, Scholz H, Keusch G, Buchholz B, Frei U, Bauer C, Kurtz A: Erythropoietin in polycystic kidneys. J Clin Invest 84: 1160–1166, 1989.PubMedGoogle Scholar
  175. 175.
    Luke RG, Kennedy AC, Stirling WB, MacDonald GA: Renal artery stenosis, hypertension and polycythemia. Br Med J 1: 164–166, 1965.PubMedGoogle Scholar
  176. 176.
    Boelaert JR, Cantinieaux BF, Hariga CF, Fondu PG: Recombinant erythropoietin reverses polymorphonuclear granulocyte dysfunction in iron-overloaded dialysis patients. Nephrol Dial Transplant 5: 504–507, 1990.PubMedGoogle Scholar
  177. 177.
    Greene HG, Ray C, Mauer MSM, Quie PG: The effect of hemodialysis on neutrophil chemotactic responsiveness. Am J Nephrol 88: 971–974, 1976.Google Scholar
  178. 178.
    Hakim RM, Stannard D, Port F, Held P: The effect of the dialysis membrane on mortality of chronic hemodialysis patients (CHD) in the U.S. (abstract). J Am Soc Nephrol 5 (3): 451, 1994.Google Scholar
  179. 179.
    Hakim RM, Wingard RL, Parker RA: Effect of the dialysis membrane in the treatment of patients with acute renal failure. N Engl J Med 331: 1338–1342, 1994.PubMedGoogle Scholar
  180. 180.
    Escolar G, Cases A, Bastida E, Garrido M, López J, Revert L, Castillo R, Ordinas A: Uremic platelets have a functional defect affecting the interaction of von Willebrand factor with glycoprotein IIb-IIIa. Blood 76: 1336–1340, 1990.PubMedGoogle Scholar
  181. 181.
    Vigano G, Gaspari F, Locatelli M, Pusineri F, Bonati M, Remuzzi G: Dose-effect and pharmacokinetics of estrogens given to correct bleeding time in uremia. Kidney Int 34: 853858, 1988.Google Scholar
  182. 182.
    Sanders PW, Taylor H, Curtis JJ: Hemodialysis without anticoagulation. Am J Kidney Dis 5: 32–35, 1985.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • J. Radermacher
    • 1
  • Karl M. Koch
    • 1
  1. 1.Abteilung Nephrologie, Zentrum Innere Medizin und DermatologieMedizinische Hochschule HannoverHannover 61Germany

Personalised recommendations